Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IBO
stocks logo

IBO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Impact Biomedical Inc (IBO.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Impact Biomedical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IBO News & Events

Events Timeline

(ET)
2025-08-18
08:38:26
Impact BioMedical Reveals U.S. Patent Issuance for 3F
select
2025-06-23 (ET)
2025-06-23
07:55:08
Impact BioMedical, Dr Ashleys enter strategic merger agreement
select
2025-02-26 (ET)
2025-02-26
08:40:42
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08-18Newsfilter
Impact Biomedical Inc (IBO) Announces Issuance of US Patent for 3F™

  • Patent Announcement: Impact Biomedical Inc. has received U.S. patent No. 12,357,584 B2 for a method to control infectious diseases using functional fragrances from its 3F™ technology platform.

  • Composition Details: The patented compositions include plant-derived constituents with antibacterial and antiviral properties, potentially effective against pathogens like E. coli, MRSA, influenza, and tuberculosis.

  • Market Potential: The global infectious disease market is expected to grow significantly, from $21.7 billion in 2024 to $34 billion by 2033, highlighting the demand for innovative healthcare solutions.

  • Company Commitment: IBO's CEO emphasized the company's dedication to developing unique technologies to address healthcare needs and is actively seeking partnerships to bring their 3F™ technology to market.

[object Object]
Preview
9.5
06-25Benzinga
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • BlackBerry's Financial Performance: BlackBerry Limited's shares rose 14.7% in pre-market trading after reporting first-quarter earnings of two cents per share, surpassing analyst expectations, and increasing its fiscal 2026 revenue guidance to between $508 million and $538 million.

  • Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with NaaS Technology Inc. surging 40.6% and XTI Aerospace, Inc. dropping 31.2% following their respective announcements and market reactions.

[object Object]
Preview
9.0
06-24Benzinga
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

  • Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.

  • Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Impact Biomedical Inc (IBO) stock price today?

The current price of IBO is 0.47 USD — it has increased 7.55 % in the last trading day.

arrow icon

What is Impact Biomedical Inc (IBO)'s business?

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

arrow icon

What is the price predicton of IBO Stock?

Wall Street analysts forecast IBO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Impact Biomedical Inc (IBO)'s revenue for the last quarter?

Impact Biomedical Inc revenue for the last quarter amounts to 18.00K USD, decreased % YoY.

arrow icon

What is Impact Biomedical Inc (IBO)'s earnings per share (EPS) for the last quarter?

Impact Biomedical Inc. EPS for the last quarter amounts to -0.12 USD, decreased -300.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Impact Biomedical Inc (IBO)'s fundamentals?

The market is revising No Change the revenue expectations for IBO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.31%.
arrow icon

How many employees does Impact Biomedical Inc (IBO). have?

Impact Biomedical Inc (IBO) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Impact Biomedical Inc (IBO) market cap?

Today IBO has the market capitalization of 48.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free